Induction of Donor Specific Tolerance in Recipients of Cardiac Allografts by Donor Stem Cell Infusion

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00497757
Recruitment Status : Completed
First Posted : July 9, 2007
Last Update Posted : May 22, 2018
Information provided by (Responsible Party):
University of Louisville

July 6, 2007
July 9, 2007
May 22, 2018
July 2003
November 7, 2011   (Final data collection date for primary outcome measure)
Enriched Hematopoetic Stem Cell Engraftment [ Time Frame: One month to three years ]
Bone marrow engraftment/chimerism
Complete list of historical versions of study NCT00497757 on Archive Site
Not Provided
Tolerance induction
Not Provided
Not Provided
Induction of Donor Specific Tolerance in Recipients of Cardiac Allografts by Donor Stem Cell Infusion
1) Induction of Donor-Specific Tolerance in Recipients of Cardiac Allografts by Donor Stem Cell Infusion 2) Induction of Donor-Specific Tolerance by Donor Facilitating Cell (FC): Stem Cell Infusion in Recipients of Hepatic Allografts
The goal of this research study is to establish chimerism and avoid graft-versus-host disease in patients who need a heart transplant.

At the present time, heart transplant recipients must take anti-rejection medication to prevent rejection of the donated heart. Even with this medication, chronic rejection is the most common cause of late graft loss. The anti-rejection agents themselves are significantly toxic, with side effects including kidney damage, infection and an increased incidence of cancer. The goal of this study is to allow the patient to develop "tolerance" to the transplanted heart while maintaining a competent immune system. Tolerance enables the transplant recipient's body to recognize the transplanted organ as self rather than foreign tissue. The recipient will not try to reject the donor heart and the need for anti-rejection medication could be dramatically decreased or eliminated entirely. To accomplish this, patients in this study will receive specially treated bone marrow taken from their heart donor. Bone marrow transplant has been shown in animal studies and in humans to induce tolerance following organ transplant.

Two factors limit the application of donor marrow transplant to induce tolerance: 1) preparing the patient for transplant (conditioning); and 2) graft-versus-host disease (GVHD). Traditional conditioning destroys the recipient's immune system and requires that the marrow transplant be successful because the patient is unable to fight off infection if the donor cells do not survive. GVHD occurs when donor immune cells recognize the recipient's cells as foreign tissue and attack them. Severe GVHD can result in death. This study utilizes a new approach to conditioning which leaves the patient's immune system intact. The transplant product is depleted of GVHD-producing cells but retains tolerance-promoting facilitating cells, which are intended to ensure the donor and recipient cells coexists peacefully, a state called mixed chimerism. The toxicity of conditioning and transplantation is significantly reduced.

In this study, we will determine the appropriate cell dose to safely establish mixed chimerism following partial conditioning in heart transplant recipients. The study takes a gradual approach to increasing the cell dose to achieve mixed chimerism. We believe this study will provide a breakthrough in the approach to heart transplantation. Our goal is to evaluate the potential of safely establishing mixed chimerism to induce tolerance following heart transplant and reduce or eliminate the need for anti-rejection therapy.

Phase 1
Phase 2
Intervention Model: Single Group Assignment
Intervention Model Description:
Open label
Masking: None (Open Label)
Primary Purpose: Treatment
Heart Transplantation
Biological: enriched hematopoetic stem cell infusion
Enriched Hematopoetic Stem Cell Infusion
Experimental: Cardiac Failure Patients
Recipients treated with an enriched hematopoetic stem cell infusion from the heart donor's bone marrow
Intervention: Biological: enriched hematopoetic stem cell infusion
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
December 1, 2016
November 7, 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subject must be between the ages of 18 and 70 years and meet the institution's criteria for cardiac transplantation.
  • Subjects must have acceptable negative results for infectious disease markers done within two weeks of the bone marrow infusion.
  • Subject is receiving a first cardiac transplant.
  • Subjects receiving a multi-organ transplant (i.e., heart/kidney) may be included at the discretion of the PI and investigators.

Note: These multi-organ subjects will have identical criteria with the exception of adequate function of the affected organ to be transplanted (i.e., kidney). They are included in the total of thirty subjects to be transplanted.

  • Subject's panel reactive antibody (PRA) is <40. If the patient is plasmapheresed prior to the heart transplant, then the pre-transplant PRA will not be a consideration for inclusion/exclusion.
  • Subject must have a negative crossmatch with the donor.
  • Women who are of child bearing potential must have a negative pregnancy test (urine test within 48 hours) before TBI and agree to use reliable contraception for one year following transplant.
  • Subject is able to give informed consent.

Exclusion Criteria:

  • Clinically active bacterial, fungal, viral or parasitic infection
  • Pregnancy
  • Previous radiation therapy at a dose that would preclude TBI
  • Subject is unable to give informed consent
  • If the procedures associated with the study (i.e., delivering TBI) would significantly extend the cold ischemia time of the heart, the protocol will be abandoned and the patient will receive a conventional heart transplant.
Sexes Eligible for Study: All
18 Years to 70 Years   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
United States
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Plan to Share IPD: No
University of Louisville
University of Louisville
Not Provided
Study Director: Suzanne T Ildstad, MD University of Louisville
University of Louisville
May 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP